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1. Introduction  
          
  Prenatal diagnosis is now part of established obstetric practice in many countries. 
However, conventional methods of prenatal diagnosis of obtaining fetal tissues for 
genetic analysis, including amniocentesis and chorionic villus sampling, are invasive and 
constitute a finite risk to the unborn fetus1. At present, it is widely accepted that both 
intact fetal cells as well as cell-free fetal DNA are present in the maternal circulation and 
can be recovered for non-invasive prenatal genetic diagnosis2,96,97. However, the rarity of 
circulating fetal cells has limited the development and practical use of this approach. 
Fetal DNA is present in maternal plasma in much higher fractional concentration than 
fetal DNA in the cellular fraction of maternal blood. This important feature has made the 
robust detection of fetal DNA possible, even without special enrichment procedures. 
  As a result of these deve lopments, fetal DNA in maternal plasma has been used for the 
noninvasive prenatal diagnosis of sex-linked disorders and single gene disorders such as 
beta-thalassemia, congenital adrenal hyperplasia and achondroplasia3-5. In addition, 
quantitative aberrations of cell-free fetal DNA have also been found in various 
pregnancy-associated disorders, including preeclampsia, preterm labor and fetal trisomy 
216,7. 
  Maternal plasma DNA analysis is also useful for the noninvasive prenatal determination 
of fetal RhD blood group status in RhD - negative pregnant women8. For the management 
of Hemolytic disease of the fetus and newborn (HDFN) a reliable non-invasive approach 
to determine fetal RhD genotype would be of great clinical value. RhD genotyping would 
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also eliminate the routine administration of Rh-immunoglobulin in RhD-negative 
patients. 
  This approach has been shown by many groups to be highly accurate (See Table 1), and 
has been introduced as a routine service in several centers in Europa49,53 .  
  In this thesis, the detail protocol of noninvasive detection of fetal RhD status using   
TaqManâ real-time polymerase chain reaction (PCR) technique is going to be described.  
 
 
 
2. Rh status in Hemolytic disease of the fetus and newborn (HDFN). 
 
  Hemolytic disease of  the fetus and newborn (HDFN) represents one of the most 
significant examples in medicine of successful management of a disease and adequate 
prophylaxis. Nowadays, HDFN accounts for 5% of all perinatal deaths12. HDFN is a 
potentially fatal condition caused by maternal alloantibodies directed against paternally 
inherited antigens on fetal red cells. Rh system`s anti-D antibodies are responsible for the 
majority of clinically detectable HDFN cases. This situation is observed in Rh-negative 
mothers whose husbands are Rh-positive, and whose immunization occurred during 
pregnancy, abortion, postpartum or incompatible transfusion. 
  The initial antibodies are of immunoglobin M (IgM) nature, with a high molecular 
weight and are unlikely to cross the placenta. As a result, they do not produce fetal 
hemolysis labely in pregnancy, the IgG antibodies cross the placenta and produce 
hemolysis. Antigen D has already developed by the 35th to 45th day of gestation, which 
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explains why 4-5% of posabortion patients may become sensitized. Intravenous drug 
abuse can also lead to isoimmunization9. There are certain obstetrics events that can 
increase the risk, such as placenta preavia, ruptured placental membranes, external 
version, cesarean section, manual removal of placenta and in the early stages of 
pregnancy-abortion, ectopic pregnancy and all invasive procedures10,12 .  For example, 
amniocentesis is associated with a 0,5-1% risk of spontaneous abortion and, moreover, is 
associated with a 17% risk of transplacental haemorrhage, which, if the fetus were RhD-
positive, could boost the maternal anti-D, enhancing the risk of severe HDFN. Chorionic 
villus sampling (CVS) is associated with a similar risk of spontaneous abortion, but a 
reduced risk of transplacental haemorrhage1,10,12,. 
  On the other hand ABO incompatibility in an Rh-negative patient provides partial 
protection against primary anti Rh-isoimmunization, but not against a secondary 
immunologic response10. There is also evidence that male fetuses have more severe 
HDFN than female fetuses11. 
  According to the severity of hemolysis, HDFN will be anemic, icteroanemic, or 
hydropic. In hydropic HDFN, the hepatic parenchyma is replaced partially with 
secondary erythropoiesis tissue, which causes aportal and umbilical venous hypertension 
syndrom, as well as alterations in the metabolism of proteins, and decreased albumin. 
Both clinical conditions cause edema and ascitis, which are characteristic of hydrops. 
Frequently, fetal cardiac failure secondary to severe anemia is observed. The other two 
forms of HDFN, anemic and icteroanemic, are the result of a less severe hemolysis that 
does not compromise either the cardiocirculatory system or the protein metabolism. 
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  When RhD sensitization occurs, careful follow-up of these mothers and judicious 
intervention can result in good outcomes for most pregnancies. At present, Doppler 
measurement of middle cerebral martery peak systolic velocity constitutes the follow-up 
method of choice for fetal anemia with 100% sensitivity and 88%specificity12. Spectral 
analysis of amniotic fluid (DOD50) and ultrasound markers, such as polyhydramnion, 
cardiomegalia, splenohepatomegalia, ascitis, soft tissue edema are useful in the diagnosis 
of fetal anemia13. Intrauterine fetal transfusion is currently the therapy of choice in cases 
of severe anti-D isoimmunization. However, it has been reported, that transfusiol therapy 
before 32 weeks of gestation is associated with a higher fetal mortality rate14. Several 
studies have shown, that high-dose ¡ -globulin therapy followed by intrauterine fetal 
transfusions (IUTs) improves fetal survival15. 
  Since 1960s Rhesus (Rh) D immunoglobulin (anti-D) has been used in women who are 
Rh D-negative to prevent Rh D immunisation after giving birth to a baby who is Rh-D 
positive. Anti-D immunoglobulin is a human blood product provided by a small group of 
immunised volunteer donors. Prevention of Rh D immunisation has been a major medical 
achievement, as Rh D immunisation was a significant cause of perinatal morbidity and 
mortality in subsequent pregnancies of affected women.   
  In practice, the combination of antenatal and postnatal prophylaxis will prevent 
immunization in 96% of the high-risk cases. The remaining 4% corresponds to the 
absence or inappropriate administration of immunoglobulin when it is indicated. 
However administration of this human blood product carries a small but real risk of 
associated blood-borne infection and moreover worldwide supplies of RhD 
immunoglobulin are limited. Furthemore, about 40% of Caucasian population of the Rh-
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negative women will receive unnecessary administration of antenatal anti-D as they 
carrying a D-negative child. Haemolytic disease of the fetus and newborn, despite Rh-
immune prophylaxis, has not been eradicated, but the risk of alloimmunization has indeed 
decreased from 13%to 0,16% 16,17,21. 
 
 
2.1. Fetal RhD gene diagnosis 
 
2.1.1. Invasive prenatal diagnosis 
   
   If the laboratory parameters such as titers or tests (an indirect Coombs test) on the 
biological activity are indicative of possible fetal hemolysis in RhD-negative patients, it 
is important to know the phenotype of the fetus. Before the molecular basis of the Rh-
antigens was known, the phenotype had to be determined by serological testing of fetal 
red cells, which could be obtained by cordocentesis or chorionic villus sampling. 
  The elucidation of the molecular basis of the blood group systems allowed the 
development of PCR-based assays for blood group typing. These assays can be 
performed with fetal DNA obtained via invasive means, such as amniocentesis or 
chorionic villus sampling. The first application of fetal RhD genotyping was prenatal 
testing for fetal RhD status to indicate the requirement for anti-D prophylaxis and clinical 
management of pregnant women with anti-D18. Several methods for PCR-based RhD 
phenotyping have been published18,19. However all these methods were found to be 
expensive, invasive and present a risk to the mother and fetus1.  
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2.1.2. Noninvasive prenatal diagnosis 
      
2.1.2.1. Fetal cells in maternal circulation 
   
  As early as 1893, Schmorl described the deportation of trophoblast sprouts into the 
pulmonary circulation of pregnant women20. At present, it is widely accepted that fetal 
cells are present in maternal blood96. Lo et al. were the first to describe that fetal sex can   
be determined by examing Ychromosome-specific PCR in fetal-cell DNA isolated from 
maternal samples97. Later this group showed that fetal RhD status can be determined by 
amplification of the RhD gene sequence in maternal DNA extracted from peripheral 
blood of pregnant women24. Meanwhile, several groups have performed the fetal RhD 
genotyping from maternal plasma25,26.  
  However, the reported accuracy of these tests was low, with low specificity and 
sensitivity. This may be due to the scarcity of fetal cells (about1, 2 cell/ml maternal blood 
)27. Moreover, it has been shown that the presence of fetal cells can persist post partum. 
Bianchi et al. reported the persistence of male CD34+ progenitor cells in maternal blood 
for as long as 27 years after delivery28. It is evident that these cells from previous 
pregnancies can lead to false-positive fetal blood group typing during a new pregnancy.  
  In a large multi-centre trial investigating the approach of recovering fetal cells from the 
maternal circulation, the NIFTY study (national Institute of Child Health and 
Development Fetal Cell Isolation Study), various enrichment techniques using 
fluorescent-activated cell sorting (FACS) or magnetic activated cell sorting (MACS) and 
micromanipulation coupled to FISH analysis have been evaluated for clinical use22. Also, 
attempts at selectively culturing viable fetal cells from maternal peripheral blood have 
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been made23. This approach has proven to be too labor intensive, with discouragingly low 
detection and high false positive rates. Although the biologic availability of fetal cells has 
been demonstrated, the development of practical technology still requires further 
developments. 
  In summary, despite the development of many ingenious methods for fetal cell isolation, 
no method has been described which is both sufficiently accurate and economical enough 
to be used on a large scale. This difficulty has been impeding the actual clinical 
utilization of non-invasive prenatal testing for fetal blood group status.  
 
 
2.1.2.3. Cell - free fetal DNA in maternal plasma 
   
  The existence of cell free fetal DNA in the maternal circulation has opened new 
possibilities of non-invasive prenatal diagnosis. Cell-free fetal DNA in maternal 
circulation was first described by Lo et al. who demonstrated the presence of the Y 
sequences in maternal blood of women carrying male fetuses2. Subsequently this group 
have used quatitative real-time PCR analysis on SRY and b-globin gene sequences in 
women pregnant with a male fetus to show that fetal DNA represents » 3%(mean 25 
genome equivalents/ml; range: 3-69) of cell-free DNA in maternal plasma during the first 
trimester of pregnancy, rising to about 6%(mean 292 genome equivalents/ml; range: 77-
769) in the third trimester29. 
  Further studies shown that cell-free fetal DNA can be detected in maternal plasma 
already at the 5th week of gestation30, and is cleared rapidly from the maternal plasma 
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following delivery, with a mean half -life of 16 min (range4-30min) following Caesarien 
section31, but generally between 10 and 100 h following vaginal delivery32. 
  Shortly after the discovery of circulating cell-free fetal DNA2 in maternal blood in 1998 
Lo et al. and Fass et al. demonstrated almost simultaneously that the RhD sequence could 
be reliably amplified from the plasma of pregnant women with high sensitivity and 
specificity8,35. Since then, many groups have replicated these findings and therefore many 
studies have been published on non-invasive prenatal RhD genotyping in relatively large 
patient series (See Table 1).  
  The largest clinical experience in the noninvasive fetal RhD genotyping resides with the 
International Blood group Reference Laboratory (IBGRL) in Bristol, United Kingdom98.    
This group has been providing fetal blood group genotyping to obstetricians as part of the 
National Blood Service since 1995. In 2001, they implemented a clinical service for 
noninvasive diagnosis of RHD genotype based on initial work that showed 100% 
accuracy43.  
  Similar large-scale reports have been published reflecting multi-year experience in 
France44,45. Gautier et al. studied 283 RhD negative pregnant women with no false 
positive or negative results44. Rouillac- Le Sciellour et al. performed lange-scale pre-
diagnosis study and shown 99,5% diagnostic accuracy of multiplex fetal RhD genotyping 
using conventional and real-time PCR. The results showed that real-time PCR was more 
convenient for a diagnostic purpose however it hasn`t been found more sensitive than 
conventional PCR for the detection of plasma DNA in early pregnancy45. 
 14 
  The group from Netherlands tested 2,359 plasma samples from D-negative pregnant 
women for the presence of RhD sequences at 30 weeks of gestation using an automated 
approach with the diagnostic accuracy of 99,4%46.  
  In 2006 Geifman-Holtzman et al. published „A meta-analysis „ of diagnostic accuracy 
of noninvasive fetal Rh genotyping from maternal blood61. The results of this meta -
analysis demonstrated that the diagnostic test of determining fetal RhD type using free-
fetal DNA in maternal blood is 94,8%. The various strategies developed to target the 
RhD gene by range from uniplex to multiplex PCR system. However the various groups 
using the same protocol have shown the different diagnostic accuracies of this test (See 
Table 1). Several group have used more than 1 protocol to determine fetal status from 
materal blood36-39. Interestingly the best diagnostic accuracies were demonstrated in the 
first trimester, while it is supposed that false negative cases of this test are mainly due to 
a lack of fetal DNA in the maternal sample due to early gestation62.  
  The meta-analysis shows that the accuracy of fetal RhD determination decreased with 
the use of maternal whole blood, RNA, or fetal cell from maternal blood and maternal 
serum and plasma were found to be the best source for accurate diagnosis of fetal RhD 
type. 
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Table 1 Published studies on RhD genotyping from fetal plasma in maternal plasma 
 
References 
 
Methods 
 
No.tested 
Gestation 
(weeks) 
 
RhD 
 
 
Accuracy 
 
Controls  
 
Lo et al,19988 
Fass et 
al.199835 
Bischoff et 
al.199936 
 
Zhong et 
al.200040 
Zhang et 
al.200046 
Nelson et 
al.200147 
Finning et 
al.200243 
Costa et 
al.200242 
Legler et 
al.200241 
 
 
Turner et 
al.200348 
Johnson et 
al.200337 
Siva et 
al.200350 
 
Randen et 
al.200449 
Rijinders et  
al.200438 
 
Rouillac et 
al.200445 
Guz et al. 
200458 
 
Finnin g et 
al.200453 
Harper et 
al.200456 
Clausen et 
al.200551 
Hromadnikova 
et al. 200539 
Zhou et al. 
200552 
Gautier et al.  
200544 
Hromadnikova 
et al. 200578 
Hromadnikova 
et al. 200577 
Gonzalez et al. 
200554 
Brojer et al. 
200555 
Minon et al. 
200592 
Lazar et al. 
200757 
 
 
Real-time PCR 
PCR 
 
Nested PCR 
Fluerescence 
PCR;(serum) 
Nested RCR 
 
Real-timePCR 
 
PCR 
 
Real-time PCR 
 
Real-time PCR 
 
Real-time PCR 
 
 
 
Real-time PCR 
 
PCR 
 
PCR 
 
 
Real-time PCR 
 
Real-time PCR 
 
 
Real-time PCR 
 
Real-time PCR 
 
 
Real-time PCR 
 
Real-time PCR 
 
Real-time PCR 
 
Real-time PCR 
 
Real-time PCR 
 
Real-time PCR 
 
Real-time PCR 
 
Real-time PCR 
 
Real-time PCR 
 
Real-time PCR 
 
Real-time PCR 
 
Real-time PCR 
 
 
 
57 
31 
 
20 
 
 
22 
 
58 
 
26 
 
137 
 
102 
 
27 
 
 
 
31 
 
47 
 
26 
 
 
114 
 
72 
 
 
893 
 
45 
 
 
283 
 
2 
 
56 
 
45 
 
98 
 
274 
 
45 
 
23 
 
20 
 
255 
 
218 
 
30 
 
7-41 
16-17 
 
15-36 
 
 
10-21 
 
All three 
trimesters 
9-34 
 
8-42 
 
8-14 
 
11-38 
 
 
 
< 20 
 
18-40 
 
15-17 
 
 
6-38 
 
11-19 
 
 
All three 
trimestres 
All three 
trimesters 
 
All three 
trimesters 
18 
 
15-16 
 
11-40 
 
14-42 
 
All three 
trimesters 
11-40 
 
11-37 
 
11-16 
 
All three 
trimesters 
All three 
trimesters 
11-22 
 
exon10  
exon 7 
 
exon 7 
 
 
exon 7 
 
exon 7 
 
exon 10 
 
exons 4,5,6,10 
 
exon 10 
 
exons 4,7 
 
 
 
exon 10 
 
exons 4,5,10 
 
exons 10, 7  
 
exon 7 
 
exon 7 
 
 
 
exons  7,10 
 
exons 7,10 
 
 
exons 4,5,10 
 
exons 4,5,10 
 
exons 7,10 
 
exons 7,10 
 
exons 4,5   10 
 
exon 10 
 
exons 7,10 
 
exons 7,10 
 
exon 7 
 
exons 7,10 
intron 4 
exons 4,5, 10 
 
Exon 7 
 
 
96% 
100% 
 
70% 
 
 
95% 
 
98% 
 
100% 
 
100% 
 
100% 
 
96% 
 
 
 
90% 
 
91% 
 
98% 
 
92% 
 
99% 
 
 
 
98,9% 
 
100% 
 
 
98% 
 
100% 
 
100% 
 
100% 
 
94% 
 
100% 
 
100% 
 
100% 
 
100% 
 
99% 
 
100% 
 
95% 
 
 
HBB 
None 
 
RHCE 
 
 
SRY, HBB 
 
None 
 
None 
 
SRY 
 
Mouse galt  
 
E.coli plasmid 
DNA,RHCE,C,c,E 
 
 
ACTB 
 
None 
 
SRY,b-globin 
 
SRY 
 
SRY,ALB 
 
 
 
None 
 
SRY, GSTM1, 
RHCE 
 
SRY, CCR5 
 
SRY 
 
None 
 
RHCE,SRY 
 
SRY,GAPD,IDPs 
 
None 
 
RHCE, SRY, 
GLO 
RHCE, GLO 
 
b-globin 
 
SRY, b -actin 
 
None 
 
None 
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   The meta-analysis results show that the test meets gold standard criteria: it is accurate, 
precise, and has high sensitivity and low false-positive and low false-negative results. A 
false-positive result is probably the „preferred“ mistake of this test as it does not carry the 
same risk as a false -negative result. In the studies that were reviewed, the explanation for 
false-positive were gene variation, presence of atypical mutation, or gene deletion.  The 
studies show that the diacnostic accuracy of fetal RhD typing using cell-free fetal DNA in 
maternal plasma is more sensitive than using fetal cells. This is due to high concentration 
of cell-free fetal DNA in plasma and unlike fetal cells in maternal blood, plasma DNA 
analysis is not complicated by the effects of persistence from prior pregnancies. 
Moreover this approach was found to be rapid and not too labor intensive. 
   In some cases, where there is a high risk that the fetus may be affected by HDFN, it is 
great value to know whether the woman`s RhD-positive partner is hetero-or homozygous 
(56% in white populations) for the RhD gene. If the father is heterozygous for the D-
antigen, the fetus has a 50% chance of being RhD -negative and therefore only in cases of 
paternal RhD heterozygosity would be important to perform the fetal noninvasive RhD 
typing in maternal plasma for the detection of foetal RhD status. In small pilot studies, 
different approaches have been suggested for the determination of the zygosity of the 
RhD gene47,59. In 2000, Pertl et al. have schown that quantitative PCR assays, in 
particular real-time TaqMan PCR can be used to determine the RhD zygosity. The results 
have shown that the fluorescent PCR-based DNA test allows accurate and rapid 
determination of zygosity for the RhD gene60.  
   Since the success with detecting plasma DNA, a number of investigators have turned 
their attention to plasma RNA. In 2000 Poon et al. were the first to show that fetal RNA 
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is present in the plasma of pregnant woman33, subsequently Ng et al. have shown that 
mRNA expressed by the placenta is readily detectable in maternal plasma34. It is 
supposed that mRNA measurement in maternal plasma may be a useful tool for non-
invasive prenatal gene expressing profiling and it is expected that plasma RNA markers 
will be developed over the next few years. But in 2005 Chiu et al. demonstrated that fetal 
RhD mRNA is not detectable in maternal plasma and therefore this approach couldn`t be 
used for the prenatat fetal RhD genotyping89. 
 
 
 
3. Genetic aspects of RhD gene 
 
  The Rh blood group system is the most polymorphic of the human blood groups, 
consisting of at least 45 independent antigens and, next to ABO, is the most clinically 
significant in transfusion medicine. 
  The history of the Rh system began in 1941 with its discovery as the cause of severe 
jaundice and fetal demise, i.e. erythroblastosis fetalis64. 
  The antigens of the Rh system are located on the surface of the erythrocyte, although 
they are thought to be part of the trophoblast65. The genetic basis of the Rh blood group 
proteins has been intensely investigated in the past decade, and the polymorphisms 
responsible for most of the antigens have now been determined94. 
  Two genes (RhD, RhCE) in close proximity on chromosome 1 encode the erythrocyte 
Rh proteins, RhD and RhCE; one carries the D antigen, and the other carries CE antigen 
in various combinations (ce, ce, cE or CE)66. The genes each have ten exons, are 97% 
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identical, and arose via gene duplication. RhD and RhCE proteins differ by 32-35 of 416 
amino acids. This is in contrast to most blood group antigens, which are encoded by 
single genes with alleles that differ by only one or a few amino acids. Individuals who 
lack RhD protein, ”Rh or D negative”, most often have a complete deletion of the RhD 
gene (See Figure 1). Exceptions to this rule occur when the gene is present but not 
translated, not expressed (RhD pseudogene -RhDY) or when the epitopes of the antigen 
are composed of weak D (epitopes weakly expressed) or partial D (epitopes are absent) 
phenotypes67. 
  The D antigen comprises numerous epitopes on the six extracellular loops of the 
polytopic RhD protein. There are many variants of D, which fall, in general into two 
types: weak D, in which all D epitopes are expressed weakly; and partial D, where some 
or many D epitopes are absent. Weak D usually arises from missense mutations in RhD, 
encoding amino acid substitutions in non-extracellular domains of the RhD protein68, 
whereas most types of partial D arise from hybrid genes in which part of RhD is replaced 
by the equivalent region of RhCE, changing amino acid sequences in the extracellular 
domains69. Some partial D phenotypes are a lso caused by simple amino acid substitutions 
in extracellular domains. The complete absence of some D epitopes in partial D makes it 
possible for those D-positive individuals to produce a D-like antibody, following 
immunization with normal D-positive red cells expressing all D epitopes. 
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Figure 1. Rearrangements at the Rh locus giving rise to D-negative and Rh deletion haplotypes. 
  The structures of the RH locus (located at 1p34-36) that have been defined in various D-negative 
phenotypes and rare Rh antigen deletion phenotypes are depicted. Each RH gene is represented as 10 
boxes, each box representing an exon, where RhCE is shown as gray, RhD as black. Crosshatched boxes 
depict silent RhD alleles (eg, RhD Q41X). The position of microinsertions or deletions of DNA that cause 
or are indicative of D-negative phenotypes are shown as triagles. Because exon 8 of RhCE and RhD are of 
identical sequence and their origins are not possible to define, they are shaded according to the gene loci 
position.  
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  In 2000 Singleton et al.  identified an inactive RhD gene, so-called pseudogene (RhD y) 
in Rh D-negative Africans. RhDY contains all 10 exons, but is inactive because of two 
inactivating mutations, a 37-bp duplication in exon 4 and a nonsense mutation (Y269X) 
in exon 6, there are also four characteristic single nucleotide polymorphism (SNPs) in 
exons 4 and 5; another gene that is relatively common in Africans and produces no RhD 
antigen, despite the presence of some RhD exons, is RhD-CE-Ds, this hybrid gene 
comprises exons 1 and 2, the 5’ end of exon 3, and exons 9 and 10 from RhD, and the 
3’end of exon 3 and exons 4-8 from RhCE70.  
   In general D-negative is prevalent in Caucasians (15-17%), but less common in Black 
Africans (5%) and Asians (3%). The D-negative phenotype has arisen numerous times, 
and multiple genetic events are responsible for loss of RhD expression in different 
populations. Caucasians have a deletion of the entire RhD gene71, but Africans and 
Asians often have an inactive or silent RhD. Approximately 66% of South African, D-
negative, Black persons have RhDY. In Asians, 10-30% of D-negative phenotype are Del 
and have very low levels of D antigen not detectable by standard typing but these adsorb 
and elute anti-D, hence the name. Del often result from a mutation causing reduced 
synthesis of the 3`region of RhD. Del are less frequently in Europeans (0,027%) and 
result from an amino acid change, M295172. 
   After RhD, the two Rh antibodies that most commonly cause HDFN are anti-Rhc and 
anti-RhE. Anti-K of the kell blood group system is also a major cause of HDFN. Many 
other blood group polymorphisms, including S/s, E/e, Kp/KP, Js/Js, Fy/Fy, Jk/JK, Di/Di 
and Co/Co, result from SNPs and are associated with HDFN, but only on rare 
occasions 69. It would be feasible to develop non-invasive methods for all these 
 21 
polymorphisms, but the demand would be extremely low owing to the rarity of severe 
disease93.  
                  
 
 
                4. RhD test with TaqMan® real-time PCR                                                                            
 
  
 4.1. Summary 
 
  Determination of fetal RhD status is extremely important for prenatal RhD prophylaxis 
and for the treatment of RhD-sensitized pregnant women whose partners are 
heterozygous for the RhD gene. The discovery of cell-free fetal DNA in maternal plasma 
provides the possibility for non-invasive detection of fetal RhD status. In the present 
study, we examined a relatively large number of maternal plasma samples at risk for 
HDFN caused by RhD-alloimmunization with TaqManâ real-time-PCR assay. The aim 
was to establish a rapid and accurate method for the detection of the fetal RhD in Rh-
negative pregnant women and to further analyse the realibility of clinical application.  
  We studied 233 non-sensitized RhD-negative pregnant women and their fetuses 
(Gestation age: 6-40, mean: 26,24). DNA was extracted using automated Magna Pure TM 
LC Instrument. Fetal RhD status was detected using uniplex exon 7 TaqManâ real-time 
PCR assay and were comfirmed by the serological analysis on cord blood after delivery 
in all RhD-negative pregnant women. One sample was excluded due to  controversial 
results from two examinations. Among 232 RhD-negative women, the results from 230 
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samples were concordant with the results of serologic analysis. Two were scored as false 
negative. We achieved a 98% of sensitivity and 100% of specificity. The presence or 
absence of the fetal RhD gene could be correctly determined in 99,4% of cases. Our 
results have shown that non-invasive  fetal RhD genotyping can be performed rapidly and 
reliably using cell-free fetal DNA in maternal plasma with TaqManâ real-time-PCR 
assay. 
 
 
4.2. Materials and methods  
 
 
 4.2.1. Sample collection 
 
  Between spring 2006 and autumn 2007 the multi-centre study was evaluated at the 
Department of Transfusion Medicine, University of Goettingen, Germany. The study was 
approved by the Ethics Committee of the local institution Goettingen and informed 
consent was obtained from all study patients. 15ml EDTA- blood samples were collected 
from 1000 RhD negative pregnant woman. All blood samples were centrifuged at 
3500rpm for 10 minutes. The plasma was transfered without disturbing the buffy coat and 
recentrifuged again at 14.000rpm for 45 minutes, afterwords plasma was collected in a 
new 2ml tubes and stored at -80°C and buffy coat was stored at -80°C as well. 
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  233 plasma samples from non-sensitized RhD-negative pregnant women in the 6th to 
40th weeks (mean: 26,24) of pregnancy were transported in Basel (University Women`s 
Hospital) from Goettingen in dryice and were stored at -70°C until further proccesing.  
 
 
4.2.2. DNA isolation 
 
  DNA was isolated with the automated Magna Pure TM LC Instrument (Roche Applied 
Science). It is an automated system employing robotics, precision pipettors and glass 
magnetic particals to purify nucleic acids from a variety of sample materials (whole 
blood, blood cells, culture cells)(See Figure 2). To isolate cell-free fetal DNA from 
maternal plasma we used’’Magna Pure LC Total Nucleic Acid Isolatoin Kit –Large 
Volume,’’ the extraction protocol with a specimen volume of 1000 ml plasma; purified 
nucleic acid was deluted in 200 ml of low salt elution buffer. Other details, such as 
reagent volumes and number of reaction tips needed for the run were automatically 
calculated by the software. DNA of 200 ml volume was frozen and kept at -20°C before 
to perform the real-time PCR.  
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Figure 2. The Stepps of a Magna Pure LC DNA isolation procedure 
The figure shows samples being dissolved and simultaneously stabilized by incubation with a buffer 
containing denaturing agents and unbound substances are removed by several washing steps; the purified 
nucleic acids are then eluted in alow salt buffer.  
 
 
4.2.3. TaqManâ real-time PCR analysis 
 
   The non-invasive fetal Rh exon 7 genotyping was performed by the use of TaqManâ 
real-time PCR (Model 7000, Applied Biosystems), which is a combined thermal cycler 
and fluorescence detector with the ability to monitor the progress of individual PCR 
reactions optically.  
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  In TaqMan chemistry73, a hybridization probe included in the PCR is cleaved by the 5’ 
nuclease activity of Taq DNA polymerase only if the probe target is being amplified. 
Using a fluorogenetic probe, first synthesized by Lee et al.74,75, enables cleavage of the 
probe to be detected without post-PCR processing (See Figure 3). 
  It is already evident that the real-time PCR has a number of advantages in comparison to 
conventional PCR37,45. The advantages of TaqMan Chemistry are as follows; specific 
hybridization between probe and target is required to generate fluorescent signal, probes 
can be labeled with different, distinguishable reporter dyes, which allows amplification of 
two distinct sequences in one reaction tube, post-PCR processing is eliminated, which 
reduces assay labor and material costs. The primary disadvantage of TaqMan Chemistry 
is that the synthesis of different probes is required for different sequences. 
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Figure 3. 5’Nuclease Assay 
The figure shows that Taqman Probe and Primers anneal and extension begins. When the enzyme reaches 
the probe, the 5`nuclease activity of the enzyme begins to displace the probe. Cleavage of the probe begins 
and Reporter starts to fluoresce as it is separated from Quencher. 
 
 
 
  For the detection of fetal RhD status we used uniplex RhD exon 7 genotyping TaqMan 
system, which consisted of amplification forward primer, reverse primer and dual-labeled 
fluorescent probe, FAM [6 carboxyfluorescein] and TAMRA [6 
carboxytetramethylrhodamine] were the fluorescent reporter dye and quencher dye (See 
Table 2). The primers and probe were targeted toward the 3’untranslated region (exon 7) 
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of the RhD gene. Taqman amplification reaction were set up in a reaction volume of 25 
ml containing 2x Taqman Universal PCR master Mix (Perkin-Elmer) corresponding to 3,5 
mmol/L MgCl2, 100mmol/1 dNTPs, 0,025 U/mL AmpliTaq Gold and 0,01 U/mL 
AmpErase; 300nM of nM of each primers, 100 nM of probe and 8ml of plasma DNA.  
  Thermal cycling was initiated with a two-minute period of incubation at 50°C to allow 
time for the enzyme UNG (Uracil N-glycosyle), which destroys any contamination PCR 
amplicons (elimination of carryover dUTP labeled PCR products), to act. 
  This Step was follwed by initial denaturation for 10 minutes at 95°C, required for 
activation of AmpliTaq Gold DNA polimarase; 40 cycles was used for the denaturation at 
95°C for 15 seconds and finelly reannealing and extantion for 1 minute at 60°C. 
Amplification data were collected and analyzed by Sequence Detection System software 
(Applied Biosystems). 
 
 
 
Table 2. Primers and probe used in the detection of the RhD gene 
  
Gene Sequence Direction 
RhD Exon 7 5`-ggg TgT TgT AAC CgA gTg CTg-3 Forward 
RhD Exon 7 5`-CCggCTCCgACggTATC-3` Reverse 
RhD Exon 7 5`FAM-CCC-ACA-gCT-CCA-TCA -Tgg-gCT-ACA-A-TAMRA3 Reverse 
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4.2.4. Quality control 
 
  Plasma DNA isolation, PCR reaction mixtures and TaqMan real-time PCR reaction 
were performed in the separated aereas. Aerosol-resistent pipette tipps (Molecular 
BioProducts, San Diego, California. U.S.) were used throughout. All equipment and work 
areas were swabbed with DNA ZapTM, PCR DNA Degradation Solution (Ambion, The 
RNA Company, An Applied Biosystems Business). The TaqManâ real-time PCR 
reagents including 2x mixture, primers and probes were prealiquoted into small volumes. 
During TaqManâ real-time PCR amplification, carry-over contamination was prevented 
by the use of uracil N-glycosylase, which destroyed uracil-containing PCR products. 
Negative controls using distilled sterile water were used to check for positive signals, 
which if present would indicate contamination occuring during the process. A serial 
dilution of gDNA has been used as a positive control as well as monitoring the sensitivity 
of the reaction in each individual amplification run.  
 
 
4.2.5. Lab aquapments, consumables 
 
Sterile Serological Pipets 5-, 10-, 25ml (BD Sciences, Basel, Switzerland), Pipetboy 
(Integra Biosciences, Switzerland); Pipets 0,5-10ml, 0,1-2,5ml, 2-20ml, 20-200ml, 10-
100ml, 100-1000ml (Eppendorf Research, Germany), Pipet Tips 10, 20, 100, 200, 1000 
(Eppendorf, Germany). 
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Laminair flow (Q-BIO gene, Germany), Laminair flow (LaminAirâ Hb 2460, Heraeus 
Instruments, Germany). 
Benchtop centrifuge for 15-and 50 ml Falcon-tubes (MultlFUGE 3s, Heraeus, Germany), 
Benchtop centrifuge for 1,5- and 2ml eppendorf tubes (Centrifuge 5415 D, Eppendorf, 
Germany), Benchtop centrifuge for 1,5-and 2ml(Qualitron, INC, Korea)  
Vortex Juergens ( Heidolph No. 54 119, Germany ). 
Magna Pure LC (LCPG 0289 Roche Diagnostics GmbH), Magna Pure LC DNA Isolation 
Kit (No.03 310 515 001,Roche Diagnostics GmbH), MagNa Pure LC Cartridge Seal (03 
118 827 001,Roche Diagnostics GmbH). Magna Pure LC Reagent Tubs;Tip Stannds,Tub 
Lids,Reaction Tips (Roche diagnostics GmbH). 
ABI Prismâ7000 Sequence detection System (Applied Biosystems, USA), PCR 
detection plate (Abgene, AB-1100,UK), Asolute QPCR Seal (Abgene,AB-1170,UK). 
 
 
4.3. Results 
      
 
4.3.1. Validation of the assay 
 
   To determine the sensitivity of RhD TaqManâ real-time-PCR analysis, genomic DNA 
from an RhD-positive subject was diluted serially in water. Subsequently the standard 
curve was constructed according 10-fold dilution series with known concentrations - 
33ng, 3,3ng, 0,33ng, 0,033ng of gDNA. The software with the PCR instrument calculates 
the standard curve for each run based on the Threshold cycle (Ct) for each standard (See 
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Figure 4). Threshold cycles were measured in duplicates and were plotted against the 
known copy number of the standard sample. The generated standard curve covered a 
linear range of four orders of magnitude and showed linearity over the entire quantitation 
range (slope = -3,685). Based on these values, a linear regression line is plotted. The 
coefficient of linear regression (R2) was equal to 0,9915 intercept equal to 40,525. 
 
 
 
 
 
 
Figure 4. Standard curve for the real-time PCR assay for fetal RhD typing 
Each dot represents the result of duplicate amplification of each dilution. Tenfold dilutions of standard 
DNA prior to amplification were used and are presented on the x-axis, whereas the corresponding Ct values 
are presented on the y-axis. The coefficient of determination (R2), the intercept and the slope value of the 
regression curve were calculated and are indicated. 
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4.3.2. Prediction of fetal RhD in maternal plasma 
 
   We examined 233 plasma samples from non-sensitized RhD-negative pregnant women 
with TaqManâ real-time PCR assay. A Ct value of less than 40 was taken as a positive 
amplification. The presence or absence of the fetal RhD gene was arbitrarily determined 
as follows: first the samples were examined in duplicate. If the both reactions presented 
as positive, we considered the fetus to be carrying the paternal RhD gene. If the both 
reactions were negative or one of the two was positive, the sample was repeated in 
another duplicate. In total, if the fetal RhD sequence was detectable in 2 or more of the 
four reactions, the result was scored as positive. Otherwise, it was considered to be 
negative (See Figure 5). Our results were confirmed by the analysis of serological test on 
cord blood after delivary, which have been performed by the clinical diagnostic 
laboratories in Germany.  
  One sample (Gestation age: 25 weeks) was excluded due to controversial results from 
two examinations. Among 232 plasma samples, 3 were in their first trimester of 
pregnancy, 82 were from the second trimester and 147 were from the third trimester. 2 
samples were scored as false negative and no false positive results were obtained (See 
Table 3). Our results indicated that the uniplex-TaqManâ real-time PCR assay achieved 
a sensitivity of 98% (158/156), and the specificity was 100% (74/74). As a whole, the 
fetal D-Status was correctly determined in 230 of 232 cases with the diagnostic accuracy 
of 99,4%. The false negative results were obtained at the 25th and 30th weeks of gestation. 
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Figure 5. Amplification curve  
The figure shows the two replicates of the detected and undetected foetal RhD sequences.  
The treshold line shows the level of detection or the point at which a reaction reaches a fluorescent intensity 
above background. The threshold line is set in the exponentioal phase of the amplification for the most 
accurate reading; The cycle at which the sample reaches this level is called the cycle Threshold, Ct and 
Baseline shows the point of initial cycles of PCR, in which there is the little change the fluorescence signal 
 
 
 
 
Table 3. Prediction of fetal RhD type in maternal plasma from RhD-negative pregnant women 
 
                                                       Predicted RhD type/ 
                                                           Serological RhD type         
  Gestation                                                                                                              Concordance 
 
     age                                         Positives           Negatives                                            (%) 
  
 
 
1st trimester                                   3/3                       0/0                                                100 
 
2nd trimester                                60/60                    22/22                                              100 
 
3rd trimester                                93/95                    52/52                                               98                                                                                                                                 
 
4.4. Discussion 
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  To assist in the management of pregnancy when an RhD negative woman is pregnant 
with an RhD positive fetus, reliable and accurate non-invasive diagnostic methods to 
predict the fetal RhD type will be of great clinical value. It can be offered to the general 
RhD-negative obstetric population whose partners are RhD-positive, whether or not fetal 
tissue sampling is performed. Furthermore, this approach would be especially 
advantageous during the first trimester of pregnancy to plan for further investigation or 
treatment in obstetrical situations such as miscarriage, antenatal haemorrhage or 
pregnancy termination. Moreover, within the next few years, it is likely that fetal RhD 
screening of all D-pregnant women will become routine practice in countries where 
rouine antenatal anti-D prophylaxis is employed. A simple, non-invasive, fully automated 
method of predicting fetal RhD phenotype from maternal plasma would reduce wastage 
of anti-RhD Ig, making the test cost-effective. It has been supposed that the total cost of 
this assay could be around one half of the cost of antenatal immunoprophylaxis76. As  
mentioned above, administration of the anti-D immuniglobulin carries a small but real 
risk of associated blood-borne infection and moreover worldwide supplies of RhD 
immunoglobulin are limited.  
  Several studies appeared during recent years on non-invasive prenatal RhD genotyping 
in relatively large patient series (See Table 1.).  These results have shown that fetal RhD 
genotype could be determined with a high level of accuracy (close to 100%), by the 
analysis of cell-free fetal DNA in maternal plasma with real-time PCR. Several studies 
have shown that the best diagnostic accuracy of the RhD typing is in the first 
trimester42or at the beginning of the second trimester63.  Thus the early availability of 
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such reliable results gives clinicians sufficient time to plan for further tests or treatment of 
sensitized RhD-negative patients such as fetal-blood sampling and fetal transfusion, 
which are usually performed at the beginning or in the middle of second trimester.  
  In this study, we examined a large number of RhD-negative maternal plamsa samples 
from non-sensitized RhD-negative pregnant women with TaqMan real time PCR assay. 
Our results have indicated that an analysis of 233 maternal plasma samples (6 to 40 
weeks of gestation) resulted in a sensitivity of 98% and a specificity of 100%. One case 
was excluded due to  controversial results from two examinations. Our first analysis for 
this sample confidently showed that the fetus inherited the paternal RhD gene. The CT 
numbers were 35, 36, 37, 38 in quadruplicate. However, the clinical outcome confirmed 
that the fetal RhD gene was negative. We re-aquired another 1ml aliquot of plasma from 
this sample in the University Women's Hospital, Goettingen Germany. We re-performed 
the analysis with the same procedure for plasma DNA isolation as well as TaqMan real 
time PCR assay. However, the results showed that no fetal RhD gene could be detected in 
maternal plasma in the second analysis. The causes could be due to the sample 
mishandling or contamination when the plasma was processed. 
  The false-negative results were scored from two samples taken at 25 and 30 weeks of 
gestation age respectively. In our study, we have used an automated Method- “Magna 
Pure TM LC Instrument” for DNA isolation.  Magna Pure has been proved by different 
groups to be more efficient and has been considered as a quick nucleic acid extraction 
system in comparison of manual isolation of cell-free DNA involving spin columns79,80. 1 
ml of plasma was used for DNA isolation and the DNA was eluted into 200 µl of elution 
buffer. 8 µl of the eluted plasma DNA was used for TaqMan real time PCR assay. Thus, 
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the amount of the template DNA might have been too small for achieving a higher 
sensitivity. In addition, the different individuals contain variable concentration of cell- 
free fetal DNA in plasma. In future, the use of large volume of plasma for DNA isolation 
as well as the increase of the template DNA alone with the PCR total reaction volume 
might improve the sensitivity. 
  To avoid false negative results caused by insufficient cell-free fetal DNA, the possible 
need for an internal positive control to demonstrate whether a particular maternal plasma 
sample actually contains a detectable concentration of cell-free fetal DNA has been 
repeatedly discussed. Researchers have been using the  Y chromosome -specific sequences 
from male fetuses as an internal positive control40. This approach is obviously not 
applicable for the 50% of pregnancies involving female fetuses. Other potentials for 
internal controls that detect DNA sequences in fetal DNA inherited from the father and 
not present in the mother are insertion and deletion polymorphisms 81 and short tandem 
repeat sequences82. The recent successful development of fetal epigenic markers: maspin 
gene83 and RASSF1A sequences84, hold promise as a universal way to confirm that fetal 
(placental) DNA is present in maternal plasma. When applied to prenatal RhD 
genotyping, these markers allowed the detection of false-negative results caused by low 
fetal DNA concentrations in maternal plasma. These developments hold promise to allow 
the eventual widespread utilization of maternal plasma DNA analysis for the non-
invasive prenatal diagnosis of blood group mismatches between the mother and fetus. 
 We did not include in our study the real-time PCR with primers for RhDY present in 
most D-individuals of African descent, because there were no such persons in our group. 
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In general, there are very few such individuals in our population, but we may consider 
RhDY typing in the future, because of increasing migration of people. 
In general the diagnostical accuracy of uniplex RhD detection using RhD exon 7 
TaqMan system was as high as that of multiplex RhD PCR system. However several 
groups have achieved 100% diagnostic accuracies using uniplex exon 7 and multiplex 
RhD typing (See Table 1). The prenatal laboratory of Women`s Hospital Basel, where 
this work has been performed, has run a series of studies for RhD typing. This group has 
used several protocols including uniplex and multiplex PCR us ing several internal 
controls; determination of paternal zygosity has been also performed 40,90,91,95. These 
studies show that at present, it is impossible to achieve 100% diagnostic accuracy in this 
test. But in general we supposed that using either multiplex RhD genotyping or the 
increased concentration of primers and probes might improve the sensitivity of this test.  
   It is important to note that this testing strategy has been already introduced as a routine 
clinical service in a number of European centers43,93 . A number of authorities have called 
for an even wider application of this technology85. The major ethical issues that will need 
to be addressed arise from the inevitable small number of incorrect results. “False 
positives” will be of minimal importance, as the mother will receive anti-D prophylaxis 
that is not required, but “false negatives” will mean that therapy will not be given to a D-
negative woman carrying a D-positive fetus. 
Understanding and overcoming the limitations of prenatal diagnosis of fetal RhD 
determination from maternal plasma has the potential to make this test the gold standard 
test for fetal Rh genotyping because it is accurate, precise and has high sensitivity and 
specificity and low false-negative and positive results. 
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4.5. Future perspectives 
  
  Cell-free fetal DNA presents only about 3% of total maternal plasma DNA. Due to the 
predominance of maternal DNA background, only the fetal DNA sequences, which are 
completely absent from maternal genome, such as Y-chromosome specific gene, or RhD 
gene in RhD-negative pregnant women, has been reliably detected with real-time PCR 
assay. However, those fetal genes, which are slightly different from maternal genome, 
such as fetal single gene mutations, are difficult to detect just by conventional real- time 
PCR-based methods. For other blood group genotyping, e.g. fetal KEL1 gene, RhEC 
gene, new technologies have to be developed.  
  Matrix-assisted laser-desorption and ionization time-of-flight mass spectrometry 
(MALDI-TOF MS)87 has emerged as a new platform for fetal genotyping using cell-free 
fetal DNA in maternal plasma. Our group has examined a relatively large number of 
maternal plasma samples from pregnancies at risk for HFND caused by KEL1- 
alloimmunization with MALDI-TOF MS assay (manuscript accepted). This technology is 
also potentially applicable to the prenatal diagnosis of fetal RhD genotyping88. Compared 
to real-time PCR, the major disadvantage of this technology is the requirement of 
expensive instrument as well as the costy comsumable reagents. 
  As molecular methods for predicting blood group phenotypes are becoming more 
widely used in the clinical laboratory, it is important that they are properly regulated. 
One form of regulation must be an external quality assurance schema, a standard 
requirement for national clinical laboratory accreditation schemes. A European network 
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of excellence on special non-invasive advances in fetal and neonatal evaluation, funded 
by the European Union, has been established. This provides money for research, 
meetings and workshops 86, to enhance communication among workers in the field. 
     In the future it would be very useful to have a single standardized assay among the 
laboratories for the non-invasive fetal RhD detection with the diagnostic accuracy of 
100%. 
 
   
 4.6. Conclusions 
 
    The “Holy Grail” within prenatal diagnosis has been non-invasive access to fetal 
genetic material. Many years have been spent trying to isolate fetal cells for this purpose, 
with only very limited success. The molecular detection of RhD blood group using cell-
free fetal DNA with real time PCR technology is the first example in which non-invasive 
prenatal diagnosis has been successfully taken from research into clinical practice and 
promises the prospect of many important applications and developments over the next 
few years. 
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